Abstract:HIV-associated neurocognitive disorders (HAND) persist despite the successful introduction of combination antiretroviral therapy (cART). While insufficient concentration of certain antiretrovirals (ARV) may lead to incomplete viral suppression in the brain, many ARVs are found to cause neuropsychiatric adverse effects, indicating their penetration into the central nervous system (CNS). Several lines of evidence suggest shared critical roles of oxidative and endoplasmic reticulum stress, compromised neuronal energy homeostasis, and autophagy in the promotion of neuronal dysfunction associated with both HIV-1 infection and long-term cART or ARV use. As the lifespans of HIV patients are increased, unique challenges have surfaced. Longer lives convey prolonged exposure of the CNS to viral toxins, neurotoxic ARVs, polypharmacy with prescribed or illicit drug use, and age-related diseases. All of these factors can contribute to increased risks for the development of neuropsychiatric conditions and cognitive impairment, which can significantly impact patient well-being, cART adherence, and overall health outcome. Strategies to increase the penetration of cART into the brain to lower viral toxicity may detrimentally increase ARV neurotoxicity and neuropsychiatric adverse effects. As clinicians attempt to control peripheral viremia in an aging population of HIV-infected patients, they must navigate an increasingly complex myriad of comorbidities, pharmacogenetics, drug-drug interactions, and psychiatric and cognitive dysfunction. Here we review in comparison to the neuropathological effects of HIV-1 the available information on neuropsychiatric adverse effects and neurotoxicity of clinically used ARV and cART. It appears altogether that future cART aiming at controlling HIV-1 in the CNS and preventing HAND will require an intricate balancing act of suppressing viral replication while minimizing neurotoxicity, impairment of neurocognition, and neuropsychiatric adverse effects.Schematic summary of the effects exerted on the brain and neurocognitive function by HIV-1 infection, comorbidities, psychostimulatory, illicit drugs, therapeutic drugs, such as antiretrovirals, the resulting polypharmacy and aging, as well as the potential interactions of all these factors

A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs

Unraveling the Mechanisms of Neurotoxicity in HIV Type 1-Associated Dementia: Inhibition of Neuronal Synaptic Transmission by Macrophage Secretory Products

Efavirenz and the CNS: what we already know and questions that need to be answered

HIV-1 Infected Mononuclear Phagocyte Secretory Products Affect Neuronal Physiology Leading to Cellular Demise: Relevance for HIV-1-associated Dementia.

Suppression Of Inflammatory Neurotoxins By Highly Active Antiretroviral Therapy In Human Immunodeficiency Virus-Associated Dementia

HIV-associated Dementia: New Insights into Disease Pathogenesis and Therapeutic Interventions.

Lymphotropic virions affect chemokine receptor-mediated neural signaling and apoptosis: implications for human immunodeficiency virus type 1-associated dementia.

Macrophages, Chemokines and Neuronal Injury in HIV-1-associated Dementia.

HIV-1 Infected and Immune Competent Mononuclear Phagocytes Induce Quantitative Alterations in Neuronal Dendritic Arbor: Relevance for HIV-1-associated Dementia.

HIV-1 Reduces Aβ-Degrading Enzymatic Activities in Primary Human Mononuclear Phagocytes

Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture

The Effect of HIV Protease Inhibitors on Amyloid-β Peptide Degradation and Synthesis in Human Cells and Alzheimer’s Disease Animal Model

Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury

The Neuropathogenesis of Hiv-1 Infection

Intracellular CXCR4 Signaling, Neuronal Apoptosis and Neuropathogenic Mechanisms of HIV-1-associated Dementia

Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation in Vivo and in Vitro

Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia.

Severe mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature review

The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases

Human iPSC-derived neurons reveal NMDAR-independent dysfunction following HIV-associated insults

Neurological disorders in HIV: Hope despite challenges